Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma

NCT00397800 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma

Interventions

BIOLOGICAL: rituximab
DRUG: cyclophosphamide
DRUG: fludarabine phosphate
RADIATION: yttrium Y 90 ibritumomab tiuxetan

Sponsor

Technical University of Munich